These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 27868013)
1. Azoramide: a new drug for the treatment of type 2 diabetes? Guillen C Ann Transl Med; 2016 Oct; 4(Suppl 1):S45. PubMed ID: 27868013 [No Abstract] [Full Text] [Related]
3. Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity. Fu S; Yalcin A; Lee GY; Li P; Fan J; Arruda AP; Pers BM; Yilmaz M; Eguchi K; Hotamisligil GS Sci Transl Med; 2015 Jun; 7(292):292ra98. PubMed ID: 26084805 [TBL] [Abstract][Full Text] [Related]
4. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. Taylor JR; Dietrich E; Powell JG Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274 [TBL] [Abstract][Full Text] [Related]
5. Thoughts on the progression of type 2 diabetes drug discovery. Bhatt HB Expert Opin Drug Discov; 2015 Feb; 10(2):107-10. PubMed ID: 25534140 [TBL] [Abstract][Full Text] [Related]
6. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Burke TA; Sturkenboom MC; Ohman-Strickland PA; Wentworth CE; Rhoads GG Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):979-87. PubMed ID: 17605137 [TBL] [Abstract][Full Text] [Related]
7. Drug Delivery Systems for Diabetes Treatment. Zaric BL; Obradovic M; Sudar-Milovanovic E; Nedeljkovic J; Lazic V; Isenovic ER Curr Pharm Des; 2019; 25(2):166-173. PubMed ID: 30848184 [TBL] [Abstract][Full Text] [Related]
8. [Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes]. Toyota T Nihon Rinsho; 1999 Mar; 57(3):695-701. PubMed ID: 10199156 [TBL] [Abstract][Full Text] [Related]
9. Alternate approaches for pediatric type 1 diabetes drug development and potential regulatory approval: a perspective. Turner JR; Close KL; Fleming GA; Wherrett DK; DiMeglio LA Diabetes Care; 2015 Oct; 38(10):1986-91. PubMed ID: 26404928 [TBL] [Abstract][Full Text] [Related]
10. A Markov decision process for modeling adverse drug reactions in medication treatment of type 2 diabetes. Eghbali-Zarch M; Tavakkoli-Moghaddam R; Esfahanian F; Azaron A; Sepehri MM Proc Inst Mech Eng H; 2019 Aug; 233(8):793-811. PubMed ID: 31177917 [TBL] [Abstract][Full Text] [Related]
11. Genetics of drug response in type 2 diabetes. Tkáč I Curr Diab Rep; 2015 Jul; 15(7):43. PubMed ID: 25975599 [TBL] [Abstract][Full Text] [Related]
13. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Dobrică EC; Găman MA; Cozma MA; Bratu OG; Pantea Stoian A; Diaconu CC Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31382651 [TBL] [Abstract][Full Text] [Related]
14. Management of type 2 diabetes: new and future developments in treatment. Liao EP Am J Med; 2012 Oct; 125(10):S2-3. PubMed ID: 22998892 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatment of type 2 diabetes: injectable medications. Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic treatment of type 2 diabetes: oral medications. Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE Ann Pharmacother; 2015 May; 49(5):540-56. PubMed ID: 25667196 [TBL] [Abstract][Full Text] [Related]
17. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Sotaniemi EA; Pelkonen O; Arranto AJ; Tapanainen P; Rautio A; Pasanen M Pharmacol Toxicol; 2002 Mar; 90(3):155-60. PubMed ID: 12071338 [TBL] [Abstract][Full Text] [Related]
18. The glitazones: a new treatment for type 2 diabetes mellitus. Bradley C Intensive Crit Care Nurs; 2002 Jun; 18(3):189-91. PubMed ID: 12405274 [TBL] [Abstract][Full Text] [Related]
19. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Pratley RE Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685 [TBL] [Abstract][Full Text] [Related]
20. The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery. Pantaleao SQ; Fujii DGV; Maltarollo VG; da C Silva D; Trossini GHG; Weber KC; Scott LPB; Honorio KM Med Chem; 2017; 13(8):706-720. PubMed ID: 28530546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]